μ vs Novartis AG
μκ°μ λ°λ₯Έ μκ°μ΄μ‘ λΉκ΅
μ
$253.0B
μμ #58
Novartis AG
$262.7B
μμ #56
μκ°μ λ°λ₯Έ μκ°μ΄μ‘
μ£Όμ μκ°
- Novartis AGμ΄(κ°) 1998λ κΉμ§ μμ(λ₯Ό) μΆμνμ΅λλ€
- μμ΄(κ°) 1999λ κΉμ§ Novartis AGμ(λ₯Ό) μΆμνμ΅λλ€
- Novartis AGμ΄(κ°) 2000λ κΉμ§ μμ(λ₯Ό) μΆμνμ΅λλ€
- μμ΄(κ°) 2002λ κΉμ§ Novartis AGμ(λ₯Ό) μΆμνμ΅λλ€
- Novartis AGμ΄(κ°) 2015λ κΉμ§ μμ(λ₯Ό) μΆμνμ΅λλ€
- μμ΄(κ°) 2016λ κΉμ§ Novartis AGμ(λ₯Ό) μΆμνμ΅λλ€
- Novartis AGμ΄(κ°) 2019λ κΉμ§ μμ(λ₯Ό) μΆμνμ΅λλ€
- μμ΄(κ°) 2023λ κΉμ§ Novartis AGμ(λ₯Ό) μΆμνμ΅λλ€
- Novartis AGμ΄(κ°) 2024λ κΉμ§ μμ(λ₯Ό) μΆμνμ΅λλ€
μ°λλ³ λΉκ΅
| μ°λ | μ | Novartis AG | μ λ |
|---|---|---|---|
| 2026 | $253.0B | $262.7B | Novartis AG |
| 2025 | $200.1B | $227.3B | Novartis AG |
| 2024 | $163.8B | $177.6B | Novartis AG |
| 2023 | $165.2B | $163.8B | μ |
| 2022 | $137.5B | $146.3B | Novartis AG |
| 2021 | $102.0B | $134.5B | Novartis AG |
| 2020 | $79.4B | $134.7B | Novartis AG |
| 2019 | $126.9B | $142.4B | Novartis AG |
| 2018 | $117.8B | $110.8B | μ |
| 2017 | $127.4B | $104.0B | μ |
| 2016 | $97.2B | $89.6B | μ |
| 2015 | $75.8B | $100.4B | Novartis AG |
| 2014 | $104.0B | $103.4B | μ |
| 2013 | $105.4B | $76.6B | μ |
| 2012 | $96.6B | $59.2B | μ |
| 2011 | $97.5B | $52.5B | μ |
| 2010 | $85.0B | $51.1B | μ |
| 2009 | $72.3B | $50.7B | μ |
| 2008 | $59.8B | $44.5B | μ |
| 2007 | $90.8B | $50.6B | μ |
| 2006 | $73.6B | $55.9B | μ |
| 2005 | $61.6B | $53.9B | μ |
| 2004 | $54.7B | $43.8B | μ |
| 2003 | $47.8B | $42.0B | μ |
| 2002 | $38.4B | $36.9B | μ |
| 2001 | $41.4B | $43.1B | Novartis AG |
| 2000 | $49.9B | $50.7B | Novartis AG |
| 1999 | $48.8B | $40.7B | μ |
| 1998 | $37.6B | $46.3B | Novartis AG |
| 1997 | $41.3B | $40.1B | μ |
| 1996 | $31.6B | $24.5B | μ |
| 1995 | $25.1B | $16.9B | μ |